Compounded Peptides ·
Novo Nordisk's semaglutide-containing products Wegovy and Ozempic have seen analogous shortage resolution dynamics. FDA updated the shortage status of various semaglutide strengths through 2024 and 2025, ultimately removing the remaining semaglutide shortage designations in early 2025. This triggered a compounded-semaglutide wind-down parallel to the one affecting compounded tirzepatide, though Novo Nordisk has so far pursued enforcement somewhat more cautiously than Eli Lilly. The compounding industry has argued that semaglutide remains effectively in shortage due to pricing and access constraints, but FDA has reiterated that the statutory definition depends on manufacturer supply capacity, not affordability.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.